Australian researchers have identified a molecular pathway that appears to regulate the spread of triple-negative breast cancer (TNBC), raising the possibility of using an existing cancer drug to prevent metastatic tumors from developing in a subset of patients. Researchers from the University of Adelaide and the Olivia Newton-John Cancer Research Institute identified a regulatory network involving microRNA-342 (miR-342) and the E2F signaling pathway that appears to influence the ability of TNBC cells that have already disseminated from the primary tumor to develop into secondary tumors. The findings were published in EMBO Molecular Medicine.
TNBC is an aggressive subtype of breast cancer characterized by the absence of estrogen receptors, progesterone receptors, and HER2 overexpression. Because these molecular targets are absent, patients with TNBC have fewer established targeted treatment options than those with hormone receptor-positive or HER2-positive disease. TNBC also has a relatively high risk of early recurrence and distant metastasis, which contributes substantially to mortality.
The researchers found that low levels of miR-342 together with increased E2F pathway activity were associated with a greater likelihood of metastatic disease. Preclinical experiments suggested that miR-342 functions as an important regulator of genes involved in tumor progression. When miR-342 levels decline, E2F signaling becomes overactive, potentially creating conditions that allow disseminated tumor cells to survive and subsequently develop into metastatic tumors.
Importantly, restoring miR-342 expression substantially reduced metastatic spread in experimental models, including the development of tumors in organs such as the lungs and bones. These findings suggest that the miR-342–E2F network may have an important role not only in the behavior of the primary tumor but also in the later stages of metastasis, when disseminated cancer cells establish themselves in distant organs.
The study also identified a potential therapeutic opportunity involving palbociclib, a cyclin-dependent kinase 4/6 (CDK4/6) inhibitor already used for certain patients with advanced hormone receptor-positive breast cancer. In experimental models characterized by low miR-342, palbociclib reduced the growth of metastatic tumors. The findings suggest that targeting the CDK4/6–E2F axis could potentially counteract the biological consequences of reduced miR-342 activity.
The potential significance of this approach lies in its timing. Rather than targeting only the primary breast tumor, CDK4/6 inhibition could potentially prevent microscopic deposits formed by disseminated tumor cells from progressing into established metastatic lesions. This raises the possibility of using an existing drug in a carefully selected subgroup of patients with TNBC who have a specific molecular profile.
The findings also raise the possibility that miR-342 could serve as a biomarker to identify patients whose tumors have increased E2F pathway activity and may therefore be particularly susceptible to CDK4/6 inhibition. Such biomarker-guided treatment could help move TNBC management toward greater molecular precision by identifying patients who may benefit from therapies directed at specific mechanisms underlying metastatic progression.
However, the findings remain preclinical and do not establish palbociclib as a treatment for TNBC. Further validation in patient-derived models and, subsequently, well-designed clinical trials will be required to determine whether miR-342 and E2F activity can reliably identify patients who benefit from CDK4/6 inhibition. The researchers have indicated that additional studies are planned before the strategy can be considered for clinical evaluation.
The study is particularly relevant because metastasis remains the major cause of mortality from breast cancer. It highlights a potential shift in therapeutic strategy from treating established metastatic disease to preventing disseminated tumor cells from progressing into clinically significant metastases. If validated in clinical studies, the miR-342–E2F pathway could provide both a biomarker for metastatic risk and a potential therapeutic target, while repurposing an established CDK4/6 inhibitor could offer a potentially faster route toward clinical translation.
References
- Arnet VK, Johnstone CN, Redvers RP, Chambers CA, Pillman KA, Toubia J, et al. Metastasis of triple negative breast cancer is regulated by a targetable miR-342-E2F network. EMBO Mol Med. 2026 Aug 21. doi:10.1038/s44321-026-00496-4.